Agios Pharmaceuticals will host a conference call on July 31, 2025, to discuss Q2 financial results and updates.
Quiver AI Summary
Agios Pharmaceuticals, Inc. announced it will host a conference call and live webcast on July 31, 2025, at 8:00 a.m. ET to discuss its second quarter financial results and business updates. The webcast will be available on the Investors section of Agios's website, with a replay accessible two hours after the event. Agios is a leader in pyruvate kinase (PK) activation, developing therapies for rare diseases, including a first-in-class PK activator for adults with PK deficiency. The company is advancing a clinical pipeline aimed at treating various conditions, such as thalassemia, sickle cell disease, and myelodysplastic syndrome, along with a preclinical treatment for polycythemia vera. For further details, individuals can visit the company’s website.
Potential Positives
- Agios is hosting a conference call to report its second quarter 2025 financial results, indicating active communication and transparency with investors.
- The company is a leader in PK activation and is dedicated to developing transformative therapies for patients with rare diseases, demonstrating a strong commitment to addressing unmet medical needs.
- Agios is advancing a robust clinical pipeline with investigational medicines aimed at multiple serious conditions, showcasing its potential for future growth and innovation in the field of rare hematologic diseases.
- Agios markets a first-in-class pyruvate kinase (PK) activator for PK deficiency, highlighting its successful introduction of disease-modifying therapies to the market.
Potential Negatives
- None
FAQ
When will Agios Pharmaceuticals report its second quarter 2025 financial results?
Agios Pharmaceuticals will report its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:00 a.m. ET.
How can I access the Agios conference call webcast?
The conference call webcast will be accessible on the Investors section of Agios' website under the “Events & Presentations” tab.
Will there be a replay of the Agios conference call?
Yes, a replay of the webcast will be available on Agios' website approximately two hours after the event.
What is Agios Pharmaceuticals known for?
Agios Pharmaceuticals is known for its leadership in pyruvate kinase activation and developing therapies for rare diseases.
What diseases does Agios' clinical pipeline focus on?
Agios' clinical pipeline focuses on diseases such as alpha- and beta-thalassemia, sickle cell disease, and pediatric PK deficiency.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AGIO Congressional Stock Trading
Members of Congress have traded $AGIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/17, 01/29 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$AGIO Insider Trading Activity
$AGIO insiders have traded $AGIO stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 4 sales selling 31,647 shares for an estimated $1,087,334.
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 7 sales selling 22,919 shares for an estimated $832,296.
- JACQUALYN A FOUSE sold 7,497 shares for an estimated $194,172
- TSVETA MILANOVA (Chief Commercial Officer) has made 0 purchases and 2 sales selling 4,451 shares for an estimated $152,648.
- JAMES WILLIAM BURNS (Chief Legal Officer) sold 2,799 shares for an estimated $93,878
- THEODORE JAMES JR. WASHBURN (Principal Accounting Officer) sold 2,272 shares for an estimated $78,134
- CECILIA JONES (Chief Financial Officer) sold 1,780 shares for an estimated $59,701
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AGIO Hedge Fund Activity
We have seen 103 institutional investors add shares of $AGIO stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP added 2,185,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $64,020,500
- JEFFERIES FINANCIAL GROUP INC. removed 1,500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,950,000
- BVF INC/IL removed 1,073,755 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $31,461,021
- BANK OF AMERICA CORP /DE/ added 730,690 shares (+180.5%) to their portfolio in Q1 2025, for an estimated $21,409,217
- SCS CAPITAL MANAGEMENT LLC added 611,098 shares (+inf%) to their portfolio in Q1 2025, for an estimated $17,905,171
- CITADEL ADVISORS LLC removed 570,177 shares (-39.8%) from their portfolio in Q1 2025, for an estimated $16,706,186
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 440,000 shares (+145.2%) to their portfolio in Q1 2025, for an estimated $12,892,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AGIO Analyst Ratings
Wall Street analysts have issued reports on $AGIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 05/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 02/24/2025
To track analyst ratings and price targets for $AGIO, check out Quiver Quantitative's $AGIO forecast page.
$AGIO Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 2 analysts offer price targets for $AGIO in the last 6 months, with a median target of $64.5.
Here are some recent targets:
- Greg Harrison from Scotiabank set a target price of $71.0 on 05/02/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $58.0 on 02/24/2025
Full Release
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its second quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website ( www.agios.com ) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at
www.agios.com
.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
[email protected]
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
[email protected]
